Clinical Trial

A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-22.
Trial Details
NCT Number NCT07615010
Lead Sponsor MiNK Therapeutics
Conditions Pneumonia
Enrollment 90 participants
Start Date 2026-05-26
Primary Completion 2027-06 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-26